Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody
Source: SeekingAlpha
2026-03-09 10:44:39 ET
More on Pfizer
- Pfizer: Obesity Hype And Vaccine Policy Shocks
- Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
- Pfizer's Quiet Cash Comeback
- Top 10 healthcare stocks with highest dividend yield amid volatile markets
- FDA plans to relax testing rules to encourage biosimilar drugs: report
Read the full article on Seeking Alpha
For further details see:
Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody
Pfizer Inc.
NASDAQ: PFE
PFE Trading
0.4% G/L:
$27.3799 Last:
19,237,113 Volume:
$27.29 Open:
PFE Latest News
PFE Stock Data
$156,612,814,520
5,628,850,476
0.02%
1712
N/A
Pharmaceuticals
Healthcare
US
New York
